'STRUCTURALLY IMPROVED': UBS analyst Michael Lasser upgraded Target ($TGT) to Buy from Neutral with a price target of $265, up from $210. The analyst believes that investors will see the company as "structurally improved," boosting shares further. Lasser also argued that Target's "strong positioning" will be more evident in the coming quarters as it maintains its momentum while lapping the more challenging quarters and as the positive impact of fiscal stimulus fades. 'FATAL BLOW' TO BEAR THESIS: Baird analyst Brian Skorney upgraded Biogen ($BIIB) to Neutral from Underperform with a price target of $382, up from $216. While the analyst disagrees with the decision, he believes the FDA approval of Aduhelm for Alzheimer's disease "deals a fatal blow" to his bear thesis. Skorney admitted that his call "has been dead wrong," and sees the investor debate now shifting to launch, payer roadblocks, and whether near-term competition can emerge from Eli Lilly ($LLY) and others with plaque reducing agents. BUY DELTA: Jefferies analyst Sheila Kahyaoglu upgraded Delta Air Lines ($DAL) to Buy from Hold with a price target of $60, up from $50. As the focus shifts from a recovery in domestic and leisure travel to corporate and international, Delta is well positioned to lead and take share, Kahyaoglu told investors. Europe is set to be the first Transocean market to open substantially to U.S. travelers, which Kahyaoglu thinks could drive greater share to Delta given 52% of its international ASMs in 2019 were deployed to Europe. ATTRACTIVE VALUATION: Argus analyst John Eade upgraded Abercrombie & Fitch ($ANF) to Buy from Hold with a $47 price target. The analyst argued that the company is improving marketing, strengthening its digital and omnichannel capabilities, and transitioning to smaller stores that can help boost customer engagement. Eade added that he is "impressed" with Abercrombie & Fitch's focus on digital sales, which now account for a majority of revenue. The analyst further stated that with price to sales multiple on the stock below peer group average, its valuation is "attractive." STABLE GROWTH: Rosenblatt analyst Blair Abernethy initiated coverage of Autodesk ($ADSK) with a Buy rating and $320 price target. Autodesk "securely retains" a leading computer aided design software franchise and has entered a period of "stable growth," Abernethy told investors in a research note. The analyst believes the company's transition to a recurring revenue model brings improved visibility and control over its business for the medium-term. The analyst also initiated coverage of PTC ($PTC) with a Buy rating and $157 price target;Ansys ($ANSS) with a Neutral rating and $340 price target. Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .